{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:03Z","timestamp":1787026983302,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:p>We report a case of thyroid eye disease (TED) reactivation, review the literature, and raise awareness of severe ophthalmopathy and myositis following the initiation of cancer treatment with an immune checkpoint inhibitor (ICI). In this case, after starting nivolumab, a 68-year-old woman with a past medical history of stage 2C uterine carcinoma status post-hysterectomy and past ocular history of thyroid eye disease developed ophthalmoplegia, proptosis, decreased color vision, optic disc hemorrhage, and ocular inflammation. Halting nivolumab and starting 2 weeks of intravenous steroids, one dose of teprotumumab, and low-dose orbital radiation resulted in an improvement in her orbitopathy. ICIs have become popular in oncologic treatment regimens, but they can have serious adverse effects including thyroiditis, Hashimoto\u2019s hypothyroidism, or Graves\u2019 disease complicated by TED. Multiple cases have been reported in the literature of both the reactivation of TED and the presentation of a TED-like orbital inflammation, which we summarize here. Awareness of orbital inflammation due to ICI use is critical, and ICIs should be used with caution in patients with a history of thyroid disease due to the risk of TED reactivation.<\/jats:p>","DOI":"10.3389\/fopht.2025.1574643","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:18:12Z","timestamp":1748956692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation"],"prefix":"10.3389","volume":"5","author":[{"given":"Samantha","family":"Madala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alomi","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Burnstine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology","volume":"4","author":"Tan","year":"2022","journal-title":"JACC Cardio Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12902-022-01004-8","article-title":"Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients","volume":"22","author":"Baek","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40123-020-00317-y","article-title":"Considerations for use of immune checkpoint inhibitors in cancer therapy for patients with co-existing thyroid eye disease","volume":"10","author":"Chau","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000485742","article-title":"Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment","volume":"7","author":"Campredon","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001161","article-title":"Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01676830.2024.2351519","article-title":"Checkpoint inhibitor-related myasthenia-myocarditis-myositis overlap syndrome in the orbit","volume":"2","author":"Park","year":"2024","journal-title":"Orbit Amst Neth"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00442","article-title":"Rapid development of graves\u2019 Ophthalmopathy after treatment with ipilimumab and recurrence with pembrolizumab in a patient with previously treated graves\u2019 Disease","volume":"14","author":"Rhea","year":"2018","journal-title":"J Oncol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit Amst Neth"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2022.2074049","article-title":"Ipilimumab-related orbitopathy: a case report","volume":"43","author":"Jebaraj","year":"2024","journal-title":"Orbit"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000509","article-title":"Inflammatory orbitopathy associated with ipilimumab","volume":"33","author":"Sheldon","year":"2017","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biologic therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/01658107.2017.1368090","article-title":"Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management","volume":"42","author":"Hassanzadeh","year":"2017","journal-title":"Neuro-Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.3.371","article-title":"Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody","volume":"17","author":"Camacho","year":"2008","journal-title":"Expert Opin Invest Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1392956","article-title":"Immune checkpoints: new insights into the pathogenesis of thyroid eye disease","volume":"15","author":"Shu","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: A systematic review","volume":"12","author":"Yu","year":"2020","journal-title":"Eye Brain"},{"key":"B18","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1574643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:18:12Z","timestamp":1748956692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1574643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":21,"alternative-id":["10.3389\/fopht.2025.1574643"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2025.1574643","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"article-number":"1574643"}}